Duobrii vs. Cosentyx

• Are Duobrii and Cosentyx the Same Thing?
• What Are Possible Side Effects of Duobrii?
• What Are Possible Side Effects of Cosentyx?
• What Is Duobrii?
• What Is Cosentyx?
• What Drugs Interact with Duobrii?
• What Drugs Interact with Cosentyx?
• How Should Duobrii Be Taken?
• How Should Cosentyx Be Taken?

Duobrii (halobetasol propionate and tazarotene) Lotion and Cosentyx (secukinumab) for Injection are used to treat plaque psoriasis in adults.

Duobrii Lotion is a topical (for the skin) treatment and Cosentyx is given as a subcutaneous injection.

Duobrii and Cosentyx belong to different drug classes. Duobrii is a combination of a corticosteroid and a retinoid and Cosentyx is a human interleukin-17A antagonist.

Side effects of Duobrii that are different from Cosentyx include contact dermatitis, application site pain, infected hair follicles, thinning skin, skin abrasions, rash, stretch marks, and skin peeling.

Side effects of Cosentyx that are different from Duobrii include sore throat and nose, diarrhea, upper respiratory tract infection, sinus infection (sinusitis), stuffy or runny nose, oral herpes, hives, athlete's foot, tonsillitis, oral thrush, impetigo, inflammatory bowel disease, ear infection, eye infection or inflammation (conjunctivitis), increased liver transaminases, and low white blood cell count (neutropenia).

Duobrii may interact with corticosteroids taken by mouth or injection and other products used on your skin that contain corticosteroids.

Cosentyx may interact with warfarin, cyclosporine, and "live" vaccines.

Common side effects of Duobrii include:

• contact dermatitis,
• application site pain,
• infected hair follicles,
• thinning skin,
• skin abrasions,
• rash,
• stretch marks, and
• skin peeling

Common side effects of Cosentyx include:

• sore throat and nose,
• diarrhea,
• upper respiratory tract infection,
• sinus infection (sinusisits),
• stuffy or runny nose,
• oral herpes,
• hives,
• athlete's foot,
• tonsillitis,
• oral thrush,
• impetigo,
• inflammatory bowel disease,
• ear infection,
• eye infection or inflammation (conjunctivitis),
• increased liver transaminases, and
• low white blood cell count (neutropenia).

Duobrii (halobetasol propionate and tazarotene) Lotion is a combination of a corticosteroid and a retinoid indicated for the topical treatment of plaque psoriasis in adults.

Cosentyx (secukinumab) for Injection is a human interleukin-17A antagonist used to treat moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Duobrii Lotion may interact with corticosteroids taken by mouth or injection, or other products used on your skin that contain corticosteroids. Tell your doctor all medications and supplements you use. Duobrii Lotion is not recommended for use during pregnancy; it may harm a fetus. A negative result for pregnancy should be obtained within 2 weeks prior to Duobrii Lotion therapy, which should begin during menstruation. Females of reproductive potential are advised to use effective contraception during treatment with Duobrii Lotion. It is unknown if Duobrii passes into breast milk.

Cosentyx may interact with abatacept, anakinra, warfarin, cyclosporine, theophylline, and live vaccines.

Apply a thin layer dose of Duobrii Lotion to the affected areas once daily.

The recommended dose of Cosentyx is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 mg dose is given as 2 subcutaneous injections of 150 mg.